WallStSmart

Chemed Corp (CHE)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 100% more annual revenue ($5.06B vs $2.53B). CHE leads profitability with a 10.5% profit margin vs 6.8%. CHE appears more attractively valued with a PEG of 1.60. ENSG earns a higher WallStSmart Score of 57/100 (C).

CHE

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 8.0Value: 7.3Quality: 7.0
Piotroski: 3/9Altman Z: 5.81

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CHESignificantly Overvalued (-270.8%)

Margin of Safety

-270.8%

Fair Value

$124.85

Current Price

$374.02

$249.17 premium

UndervaluedFair: $124.85Overvalued
ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CHE3 strengths · Avg: 9.3/10
Altman Z-ScoreHealth
5.8110/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

Areas to Watch

CHE4 concerns · Avg: 2.8/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EPS GrowthGrowth
-9.1%2/10

Earnings declined 9.1%

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CHE

The strongest argument for CHE centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bear Case : CHE

The primary concerns for CHE are PEG Ratio, Piotroski F-Score, Revenue Growth.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Key Dynamics to Monitor

CHE profiles as a declining stock while ENSG is a growth play — different risk/reward profiles.

ENSG carries more volatility with a beta of 0.80 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (57/100 vs 51/100) and 20.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chemed Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Visit Website →

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?